MWNA
IMCR icon

Marshall Wace North America’s Immunocore IMCR Stock Holding History

Marshall Wace North America’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$932K Hold
25,144
– – ﹤0.01% 946
2021
Q2 		$982K Sell
25,144
-36,614
-59% -$1.41M ﹤0.01% 1014
2021
Q1 		$2.63M Buy
+61,758
New +$2.75M 0.01% 739

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Marshall Wace North America's IMCR Position: Q3 2021 in Review

Marshall Wace North America held its Immunocore (IMCR) position steady in Q3 2021 at 25,144 shares worth $932K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Marshall Wace North America first reported a position in IMCR in Q1 2021 and has held it in 3 quarters since. The position peaked at $2.63M in Q1 2021. 47 funds tracked by Wall St. Rank hold IMCR as of Q3 2021.

  • Marshall Wace North America held 25,144 shares of Immunocore worth $932K as of Q3 2021.
  • Marshall Wace North America left its Immunocore share count unchanged in Q3 2021.
  • Immunocore made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #946 holding.
  • Marshall Wace North America first reported a position in Immunocore in Q1 2021 and has held it in 3 quarters since.
  • Marshall Wace North America's Immunocore position peaked at $2.63M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Immunocore as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.